查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1612525

BETA阻斷劑市場：按類型、應用和分銷管道分類 - 2025-2030 年全球預測

Beta Blockers Market by Type (Beta Non-selective Blocker, Beta-1 Selective Blocker), Application (Cardiac Diseases, Glaucoma, Hypertension), Distribution Channel - Global Forecast 2025-2030
出版日期: | 出版商: 360iResearch | 英文 192 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

2023年BETA阻斷劑市值為105.4億美元，預計2024年將達到110.6億美元，複合年成長率為5.23%，到2030年將達到150.8億美元。

BETA阻斷劑或BETA-腎上腺素阻斷劑是主要用於治療各種心血管疾病的藥物，包括高血壓、心律不整和心臟衰竭。其範圍也擴展到治療焦慮、偏頭痛和某些類型的青光眼，凸顯了其需求和多功能性。這些藥物透過抑制腎上腺素的作用、降低心率和血壓來發揮作用。心血管疾病盛行率上升、人口老化以及人們對治療選擇的認知不斷提高，推動了BETA阻斷劑的全球市場。 BETA阻斷劑在醫院、診所和零售藥局都有應用，展示了其廣泛的最終用途。配方技術的進步、醫療保健支出的增加以及加強公共衛生基礎設施的努力對產業成長產生了重大影響。學名藥的興起為新興市場帶來了潛在的商機，促進了競爭性定價和擴大了准入範圍。公司可以透過投資創新的藥物輸送系統並開拓開拓的當地市場來利用這些動態。然而，它面臨著監管障礙、嚴格的藥物核准以及與長期使用相關的副作用等挑戰，這可能會阻礙市場成長。此外，某些地區的經濟不穩定可能會影響醫療保健預算，最終影響藥品購買。在創新和研究方面，開發具有更少或更多針對性副作用的遞送系統可以提供競爭優勢。此外，專注於遺傳因素和生活習慣以實現更有效治療的個人化醫療方法是成熟的研究領域。該市場的特點是競爭激烈，主要企業不斷投資研發以維持和擴大市場佔有率。因此，希望發展BETA阻斷劑市場的公司必須專注於創新、策略夥伴關係關係，並擴大其在開拓市場的影響力，以利用新的機會。

主要市場統計
基準年[2023] 105.4億美元
預測年份 [2024] 110.6億美元
預測年份 [2030] 150.8億美元
複合年成長率（%） 5.23%

市場動態：快速發展的BETA阻斷劑市場的關鍵市場洞察

供需的動態交互作用正在改變BETA阻斷劑市場。透過了解這些不斷變化的市場動態，公司可以準備好做出明智的投資決策、完善策略決策並抓住新的商機。全面了解這些趨勢可以幫助企業降低政治、地理、技術、社會和經濟領域的風險，同時也能幫助消費行為及其對製造業的影響。

  • 市場促進因素
    • 人口老化加劇，更容易罹患心臟病
    • BETA阻斷劑在治療鬱血性心臟衰竭、心律不整和甲狀腺功能亢進中的作用日益增強
    • 政府和醫療保健組織的公共衛生舉措和意識提升計劃
  • 市場限制因素
    • 發生產品召回事件
  • 市場機會
    • 活性化活動以開發治療高血壓的個人化BETA阻斷劑
    • BETA阻斷劑新分析方法的趨勢
  • 市場挑戰
    • 與服用BETA阻斷劑相關的副作用

波特的五力：駕馭BETA阻斷劑市場的策略工具

波特的五力架構是了解BETA阻斷劑市場競爭格局的重要工具。波特的五力框架為評估公司的競爭地位和探索策略機會提供了清晰的方法。該框架可幫助公司評估市場動態並確定新業務的盈利。這些見解使公司能夠利用自己的優勢、解決弱點並避免潛在的挑戰，以確保更強大的市場地位。

PESTLE分析：了解BETA阻斷劑市場的外部影響

外部宏觀環境因素在塑造BETA阻斷劑市場的表現動態方面發揮著至關重要的作用。對政治、經濟、社會、技術、法律和環境因素的分析提供了應對這些影響所需的資訊。透過調查 PESTLE 因素，公司可以更了解潛在的風險和機會。這種分析可以幫助公司預測法規、消費者偏好和經濟趨勢的變化，並為他們做出積極主動的決策做好準備。

市場佔有率分析 了解BETA阻斷劑市場的競爭狀況

對BETA阻斷劑市場的詳細市場佔有率分析可以對供應商的績效進行全面評估。公司可以透過比較收益、客戶群和成長率等關鍵指標來揭示其競爭地位。該分析揭示了市場集中、分散和整合的趨勢，為供應商提供了製定策略決策所需的洞察力，使他們能夠在日益激烈的競爭中佔有一席之地。

FPNV 定位矩陣BETA阻斷劑市場供應商的績效評估

FPNV 定位矩陣是評估BETA阻斷劑市場供應商的重要工具。此矩陣允許業務組織根據供應商的商務策略和產品滿意度評估供應商，從而做出符合其目標的明智決策。這四個象限使您能夠清晰、準確地分類供應商，以確定最能滿足您的策略目標的合作夥伴和解決方案。

策略分析與建議，為BETA阻斷劑市場的成功指明道路

對於旨在加強在全球市場的影響力的公司來說， BETA阻斷劑市場的策略分析至關重要。透過考慮關鍵資源、能力和績效指標，公司可以識別成長機會並努力改進。這種方法使您能夠克服競爭環境中的挑戰，利用新的商機，並取得長期成功。

本報告對市場進行了全面分析，涵蓋關鍵重點領域：

1. 市場滲透率：對當前市場環境的詳細審查、主要企業的廣泛資料、對其在市場中的影響力和整體影響力的評估。

2. 市場開拓：辨識新興市場的成長機會，評估現有領域的擴張潛力，並提供未來成長的策略藍圖。

3. 市場多元化：分析近期產品發布、開拓地區、關鍵產業進展、塑造市場的策略投資。

4. 競爭評估與情報：徹底分析競爭格局，檢驗市場佔有率、業務策略、產品系列、認證、監理核准、專利趨勢、主要企業的技術進步等。

5. 產品開發與創新：重點在於有望推動未來市場成長的最尖端科技、研發活動和產品創新。

我們也回答重要問題，幫助相關人員做出明智的決策：

1.目前的市場規模和未來的成長預測是多少？

2. 哪些產品、區隔市場和地區提供最佳投資機會？

3.塑造市場的主要技術趨勢和監管影響是什麼？

4.主要廠商的市場佔有率和競爭地位如何？

5. 推動供應商市場進入和退出策略的收益來源和策略機會是什麼？

目錄

第1章 前言

第2章調查方法

第3章執行摘要

第4章市場概況

第5章市場洞察

  • 市場動態
    • 促進因素
      • 隨著人口老化，人們更容易罹患心臟病
      • BETA阻斷劑在治療鬱血性心臟衰竭、心律不整和甲狀腺功能亢進中的作用日益增強
      • 政府和醫療機構的公共衛生舉措和意識計劃
    • 抑制因素
      • 產品召回發生率
    • 機會
      • 擴大研發 (R&D) 活動，開發個人化的BETA阻斷劑治療高血壓
      • BETA阻斷劑分析方法的新趨勢
    • 任務
      • 與服用BETA阻斷劑相關的副作用
  • 市場區隔分析
    • 類型：增加 BETA1-選擇性阻斷劑的消費量以解決呼吸道疾病問題
    • 應用：擴大使用BETA阻斷劑作為腎上腺素來治療各種心血管疾病
  • 波特五力分析
  • PESTEL分析
    • 政治的
    • 經濟
    • 社群
    • 技術的
    • 合法地
    • 環境

第6章BETA阻斷劑市場：依類型

  • Beta非選擇性阻斷劑
    • 拉貝洛爾
    • 硫酸戊布醇
    • 吲哚洛爾
    • 鹽酸索他洛爾
  • beta1選擇性阻斷劑
    • 醋丁洛爾
    • 阿替洛爾
    • 比索洛爾
    • 美托洛爾

第7章BETA阻斷劑市場：依應用分類

  • 心臟病
    • 心絞痛
    • 心房顫動
    • 心臟衰竭
  • 青光眼
  • 高血壓

第 8 章BETA阻斷劑市場：按分銷管道

  • 醫院藥房
  • 零售藥房

第9章 美洲BETA阻斷劑市場

  • 阿根廷
  • 巴西
  • 加拿大
  • 墨西哥
  • 美國

第10章亞太地區BETA阻斷劑市場

  • 澳洲
  • 中國
  • 印度
  • 印尼
  • 日本
  • 馬來西亞
  • 菲律賓
  • 新加坡
  • 韓國
  • 台灣
  • 泰國
  • 越南

第11章 歐洲、中東和非洲的BETA阻斷劑市場

  • 丹麥
  • 埃及
  • 芬蘭
  • 法國
  • 德國
  • 以色列
  • 義大利
  • 荷蘭
  • 奈及利亞
  • 挪威
  • 波蘭
  • 卡達
  • 俄羅斯
  • 沙烏地阿拉伯
  • 南非
  • 西班牙
  • 瑞典
  • 瑞士
  • 土耳其
  • 阿拉伯聯合大公國
  • 英國

第12章競爭格局

  • 2023 年市場佔有率分析
  • FPNV 定位矩陣，2023
  • 競爭情境分析
    • FDA核准VELSIPITY 用於治療活動性潰瘍性大腸炎
    • “一種新的超短效BETA受體阻斷劑蘭地洛爾已在加拿大獲得核准用於治療嚴重的心臟病。”
    • Ajanta Pharma 推出新型雙效片劑“Met-XL AMT”，用於簡單有效的高血壓管理
  • 戰略分析和建議

公司名單

  • AdvaCare Pharma
  • Amneal Pharmaceuticals LLC
  • ANI Pharmaceuticals, Inc.
  • AstraZeneca PLC
  • Baxter International Inc.
  • Bayer AG
  • Boehringer Ingelheim International GmbH
  • Bristol-Myers Squibb Company
  • Cipla Limited
  • DAIICHI SANKYO COMPANY, LIMITED
  • Dr. Reddy's Laboratories Ltd.
  • Eagle Pharmaceuticals, Inc.
  • GlaxoSmithKline PLC
  • Lupin Limited
  • Merck & Co., Inc.
  • Neuracle Lifesciences Private Limited
  • Novartis AG
  • Pfizer Inc.
  • Recordati Industria Chimica e Farmaceutica SpA
  • Sun Pharmaceutical Industries Ltd.
  • Teva Pharmaceutical Industries Ltd.
  • The Menarini Group
  • Viatris Inc.
Product Code: MRR-7A22CB0E64F1

The Beta Blockers Market was valued at USD 10.54 billion in 2023, expected to reach USD 11.06 billion in 2024, and is projected to grow at a CAGR of 5.23%, to USD 15.08 billion by 2030.

Beta blockers, or beta-adrenergic blocking agents, are pharmaceuticals primarily used to manage various cardiovascular conditions, including hypertension, arrhythmias, and heart failure. Their scope extends into treating anxiety, migraines, and certain types of glaucoma, highlighting their necessity and versatility. These medications function by inhibiting the effects of adrenaline, resulting in lowered heart rates and blood pressure. The global market for beta blockers is driven by rising cardiovascular disease prevalence, aging populations, and increasing awareness of treatment options. The application of beta blockers spans hospitals, clinics, and retail pharmacies, demonstrating their extensive end-use scope. Industry growth is significantly influenced by technological advancements in drug formulations, increasing healthcare spending, and initiatives to enhance public health infrastructure. The rise in generic drug formulations presents potential opportunities in emerging markets, encouraging competitive pricing and widening access. Companies can leverage these dynamics by investing in innovative drug delivery systems or exploring untapped rural markets. However, the market faces challenges, such as regulatory hurdles, strict drug approvals, and side effects associated with long-term use, which could inhibit growth. Additionally, economic instability in certain regions can impact healthcare budgets and, consequently, pharmaceutical purchases. In terms of innovation and research, developing beta blockers with fewer side effects or targeted delivery systems could offer a competitive edge. Furthermore, personalized medicine approaches, focusing on genetic and lifestyle factors for more effective treatment, present an area ripe for research. The market is characterized by high competition, with key players constantly investing in R&D to maintain or increase market share. Thus, businesses aiming for growth in the beta blockers market should focus on innovation, strategic partnerships, and expanding their presence in underserved markets to capitalize on unfolding opportunities.

KEY MARKET STATISTICS
Base Year [2023] USD 10.54 billion
Estimated Year [2024] USD 11.06 billion
Forecast Year [2030] USD 15.08 billion
CAGR (%) 5.23%

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving Beta Blockers Market

The Beta Blockers Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

  • Market Drivers
    • Rising aging population more susceptible to heart-related conditions
    • Increasing role of beta blockers in managing congestive heart failure, cardiac arrhythmias, and hyperthyroidism
    • Public health initiatives and awareness programs by governments and healthcare organizations
  • Market Restraints
    • Incidence of product recall
  • Market Opportunities
    • Growing research and development (R&D) activities for the development of individualized beta-blocker treatment for high blood pressure
    • Novel trends in analytical methods for beta blockers
  • Market Challenges
    • Side effects associated with the consumption of beta blockers

Porter's Five Forces: A Strategic Tool for Navigating the Beta Blockers Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the Beta Blockers Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the Beta Blockers Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the Beta Blockers Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the Beta Blockers Market

A detailed market share analysis in the Beta Blockers Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the Beta Blockers Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the Beta Blockers Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Strategy Analysis & Recommendation: Charting a Path to Success in the Beta Blockers Market

A strategic analysis of the Beta Blockers Market is essential for businesses looking to strengthen their global market presence. By reviewing key resources, capabilities, and performance indicators, business organizations can identify growth opportunities and work toward improvement. This approach helps businesses navigate challenges in the competitive landscape and ensures they are well-positioned to capitalize on newer opportunities and drive long-term success.

Key Company Profiles

The report delves into recent significant developments in the Beta Blockers Market, highlighting leading vendors and their innovative profiles. These include AdvaCare Pharma, Amneal Pharmaceuticals LLC, ANI Pharmaceuticals, Inc., AstraZeneca PLC, Baxter International Inc., Bayer AG, Boehringer Ingelheim International GmbH, Bristol-Myers Squibb Company, Cipla Limited, DAIICHI SANKYO COMPANY, LIMITED, Dr. Reddy's Laboratories Ltd., Eagle Pharmaceuticals, Inc., GlaxoSmithKline PLC, Lupin Limited, Merck & Co., Inc., Neuracle Lifesciences Private Limited, Novartis AG, Pfizer Inc., Recordati Industria Chimica e Farmaceutica S.p.A., Sun Pharmaceutical Industries Ltd., Teva Pharmaceutical Industries Ltd., The Menarini Group, and Viatris Inc..

Market Segmentation & Coverage

This research report categorizes the Beta Blockers Market to forecast the revenues and analyze trends in each of the following sub-markets:

  • Based on Type, market is studied across Beta Non-selective Blocker and Beta-1 Selective Blocker. The Beta Non-selective Blocker is further studied across Labetalol, Penbutolol Sulfate, Pindolol, and Sotalol Hydrochloride. The Beta-1 Selective Blocker is further studied across Acebutolol, Atenolol, Bisoprolol, and Metoprolol.
  • Based on Application, market is studied across Cardiac Diseases, Glaucoma, and Hypertension. The Cardiac Diseases is further studied across Angina, Atrial Fibrillation, and Heart Failure.
  • Based on Distribution Channel, market is studied across Hospital Pharmacies and Retail Pharmacies.
  • Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. Rising aging population more susceptible to heart-related conditions
      • 5.1.1.2. Increasing role of beta blockers in managing congestive heart failure, cardiac arrhythmias, and hyperthyroidism
      • 5.1.1.3. Public health initiatives and awareness programs by governments and healthcare organizations
    • 5.1.2. Restraints
      • 5.1.2.1. Incidence of product recall
    • 5.1.3. Opportunities
      • 5.1.3.1. Growing research and development (R&D) activities for the development of individualized beta-blocker treatment for high blood pressure
      • 5.1.3.2. Novel trends in analytical methods for beta blockers
    • 5.1.4. Challenges
      • 5.1.4.1. Side effects associated with the consumption of beta blockers
  • 5.2. Market Segmentation Analysis
    • 5.2.1. Type: Rising consumption of beta-1 selective blockers to address respiratory concerns
    • 5.2.2. Application: Increasing usage of beta blockers as an adrenaline in managing various cardiovascular conditions
  • 5.3. Porter's Five Forces Analysis
    • 5.3.1. Threat of New Entrants
    • 5.3.2. Threat of Substitutes
    • 5.3.3. Bargaining Power of Customers
    • 5.3.4. Bargaining Power of Suppliers
    • 5.3.5. Industry Rivalry
  • 5.4. PESTLE Analysis
    • 5.4.1. Political
    • 5.4.2. Economic
    • 5.4.3. Social
    • 5.4.4. Technological
    • 5.4.5. Legal
    • 5.4.6. Environmental

6. Beta Blockers Market, by Type

  • 6.1. Introduction
  • 6.2. Beta Non-selective Blocker
    • 6.2.1. Labetalol
    • 6.2.2. Penbutolol Sulfate
    • 6.2.3. Pindolol
    • 6.2.4. Sotalol Hydrochloride
  • 6.3. Beta-1 Selective Blocker
    • 6.3.1. Acebutolol
    • 6.3.2. Atenolol
    • 6.3.3. Bisoprolol
    • 6.3.4. Metoprolol

7. Beta Blockers Market, by Application

  • 7.1. Introduction
  • 7.2. Cardiac Diseases
    • 7.2.1. Angina
    • 7.2.2. Atrial Fibrillation
    • 7.2.3. Heart Failure
  • 7.3. Glaucoma
  • 7.4. Hypertension

8. Beta Blockers Market, by Distribution Channel

  • 8.1. Introduction
  • 8.2. Hospital Pharmacies
  • 8.3. Retail Pharmacies

9. Americas Beta Blockers Market

  • 9.1. Introduction
  • 9.2. Argentina
  • 9.3. Brazil
  • 9.4. Canada
  • 9.5. Mexico
  • 9.6. United States

10. Asia-Pacific Beta Blockers Market

  • 10.1. Introduction
  • 10.2. Australia
  • 10.3. China
  • 10.4. India
  • 10.5. Indonesia
  • 10.6. Japan
  • 10.7. Malaysia
  • 10.8. Philippines
  • 10.9. Singapore
  • 10.10. South Korea
  • 10.11. Taiwan
  • 10.12. Thailand
  • 10.13. Vietnam

11. Europe, Middle East & Africa Beta Blockers Market

  • 11.1. Introduction
  • 11.2. Denmark
  • 11.3. Egypt
  • 11.4. Finland
  • 11.5. France
  • 11.6. Germany
  • 11.7. Israel
  • 11.8. Italy
  • 11.9. Netherlands
  • 11.10. Nigeria
  • 11.11. Norway
  • 11.12. Poland
  • 11.13. Qatar
  • 11.14. Russia
  • 11.15. Saudi Arabia
  • 11.16. South Africa
  • 11.17. Spain
  • 11.18. Sweden
  • 11.19. Switzerland
  • 11.20. Turkey
  • 11.21. United Arab Emirates
  • 11.22. United Kingdom

12. Competitive Landscape

  • 12.1. Market Share Analysis, 2023
  • 12.2. FPNV Positioning Matrix, 2023
  • 12.3. Competitive Scenario Analysis
    • 12.3.1. FDA Approved VELSIPITY, An Advancement To Treat Active Ulcerative Colitis
    • 12.3.2. "New Ultra-Short-Acting Beta Blocker, Landiolol, Received Canadian Approval For Critical Care Cardiac Conditions
    • 12.3.3. Ajanta Pharma Launched Met-XL AMT, A New Dual-Action Tablet for Simplified and Effective Hypertension Management
  • 12.4. Strategy Analysis & Recommendation

Companies Mentioned

  • 1. AdvaCare Pharma
  • 2. Amneal Pharmaceuticals LLC
  • 3. ANI Pharmaceuticals, Inc.
  • 4. AstraZeneca PLC
  • 5. Baxter International Inc.
  • 6. Bayer AG
  • 7. Boehringer Ingelheim International GmbH
  • 8. Bristol-Myers Squibb Company
  • 9. Cipla Limited
  • 10. DAIICHI SANKYO COMPANY, LIMITED
  • 11. Dr. Reddy's Laboratories Ltd.
  • 12. Eagle Pharmaceuticals, Inc.
  • 13. GlaxoSmithKline PLC
  • 14. Lupin Limited
  • 15. Merck & Co., Inc.
  • 16. Neuracle Lifesciences Private Limited
  • 17. Novartis AG
  • 18. Pfizer Inc.
  • 19. Recordati Industria Chimica e Farmaceutica S.p.A.
  • 20. Sun Pharmaceutical Industries Ltd.
  • 21. Teva Pharmaceutical Industries Ltd.
  • 22. The Menarini Group
  • 23. Viatris Inc.

LIST OF FIGURES

  • FIGURE 1. BETA BLOCKERS MARKET RESEARCH PROCESS
  • FIGURE 2. BETA BLOCKERS MARKET SIZE, 2023 VS 2030
  • FIGURE 3. GLOBAL BETA BLOCKERS MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 4. GLOBAL BETA BLOCKERS MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 5. GLOBAL BETA BLOCKERS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 6. GLOBAL BETA BLOCKERS MARKET SIZE, BY TYPE, 2023 VS 2030 (%)
  • FIGURE 7. GLOBAL BETA BLOCKERS MARKET SIZE, BY TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 8. GLOBAL BETA BLOCKERS MARKET SIZE, BY APPLICATION, 2023 VS 2030 (%)
  • FIGURE 9. GLOBAL BETA BLOCKERS MARKET SIZE, BY APPLICATION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 10. GLOBAL BETA BLOCKERS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2023 VS 2030 (%)
  • FIGURE 11. GLOBAL BETA BLOCKERS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 12. AMERICAS BETA BLOCKERS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 13. AMERICAS BETA BLOCKERS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 14. UNITED STATES BETA BLOCKERS MARKET SIZE, BY STATE, 2023 VS 2030 (%)
  • FIGURE 15. UNITED STATES BETA BLOCKERS MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 16. ASIA-PACIFIC BETA BLOCKERS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 17. ASIA-PACIFIC BETA BLOCKERS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 18. EUROPE, MIDDLE EAST & AFRICA BETA BLOCKERS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 19. EUROPE, MIDDLE EAST & AFRICA BETA BLOCKERS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 20. BETA BLOCKERS MARKET SHARE, BY KEY PLAYER, 2023
  • FIGURE 21. BETA BLOCKERS MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

  • TABLE 1. BETA BLOCKERS MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
  • TABLE 3. GLOBAL BETA BLOCKERS MARKET SIZE, 2018-2030 (USD MILLION)
  • TABLE 4. GLOBAL BETA BLOCKERS MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 5. GLOBAL BETA BLOCKERS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 6. BETA BLOCKERS MARKET DYNAMICS
  • TABLE 7. GLOBAL BETA BLOCKERS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 8. GLOBAL BETA BLOCKERS MARKET SIZE, BY BETA NON-SELECTIVE BLOCKER, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 9. GLOBAL BETA BLOCKERS MARKET SIZE, BY LABETALOL, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 10. GLOBAL BETA BLOCKERS MARKET SIZE, BY PENBUTOLOL SULFATE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 11. GLOBAL BETA BLOCKERS MARKET SIZE, BY PINDOLOL, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 12. GLOBAL BETA BLOCKERS MARKET SIZE, BY SOTALOL HYDROCHLORIDE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 13. GLOBAL BETA BLOCKERS MARKET SIZE, BY BETA NON-SELECTIVE BLOCKER, 2018-2030 (USD MILLION)
  • TABLE 14. GLOBAL BETA BLOCKERS MARKET SIZE, BY BETA-1 SELECTIVE BLOCKER, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 15. GLOBAL BETA BLOCKERS MARKET SIZE, BY ACEBUTOLOL, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 16. GLOBAL BETA BLOCKERS MARKET SIZE, BY ATENOLOL, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 17. GLOBAL BETA BLOCKERS MARKET SIZE, BY BISOPROLOL, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 18. GLOBAL BETA BLOCKERS MARKET SIZE, BY METOPROLOL, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 19. GLOBAL BETA BLOCKERS MARKET SIZE, BY BETA-1 SELECTIVE BLOCKER, 2018-2030 (USD MILLION)
  • TABLE 20. GLOBAL BETA BLOCKERS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 21. GLOBAL BETA BLOCKERS MARKET SIZE, BY CARDIAC DISEASES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 22. GLOBAL BETA BLOCKERS MARKET SIZE, BY ANGINA, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 23. GLOBAL BETA BLOCKERS MARKET SIZE, BY ATRIAL FIBRILLATION, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 24. GLOBAL BETA BLOCKERS MARKET SIZE, BY HEART FAILURE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 25. GLOBAL BETA BLOCKERS MARKET SIZE, BY CARDIAC DISEASES, 2018-2030 (USD MILLION)
  • TABLE 26. GLOBAL BETA BLOCKERS MARKET SIZE, BY GLAUCOMA, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 27. GLOBAL BETA BLOCKERS MARKET SIZE, BY HYPERTENSION, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 28. GLOBAL BETA BLOCKERS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 29. GLOBAL BETA BLOCKERS MARKET SIZE, BY HOSPITAL PHARMACIES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 30. GLOBAL BETA BLOCKERS MARKET SIZE, BY RETAIL PHARMACIES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 31. AMERICAS BETA BLOCKERS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 32. AMERICAS BETA BLOCKERS MARKET SIZE, BY BETA NON-SELECTIVE BLOCKER, 2018-2030 (USD MILLION)
  • TABLE 33. AMERICAS BETA BLOCKERS MARKET SIZE, BY BETA-1 SELECTIVE BLOCKER, 2018-2030 (USD MILLION)
  • TABLE 34. AMERICAS BETA BLOCKERS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 35. AMERICAS BETA BLOCKERS MARKET SIZE, BY CARDIAC DISEASES, 2018-2030 (USD MILLION)
  • TABLE 36. AMERICAS BETA BLOCKERS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 37. AMERICAS BETA BLOCKERS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 38. ARGENTINA BETA BLOCKERS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 39. ARGENTINA BETA BLOCKERS MARKET SIZE, BY BETA NON-SELECTIVE BLOCKER, 2018-2030 (USD MILLION)
  • TABLE 40. ARGENTINA BETA BLOCKERS MARKET SIZE, BY BETA-1 SELECTIVE BLOCKER, 2018-2030 (USD MILLION)
  • TABLE 41. ARGENTINA BETA BLOCKERS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 42. ARGENTINA BETA BLOCKERS MARKET SIZE, BY CARDIAC DISEASES, 2018-2030 (USD MILLION)
  • TABLE 43. ARGENTINA BETA BLOCKERS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 44. BRAZIL BETA BLOCKERS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 45. BRAZIL BETA BLOCKERS MARKET SIZE, BY BETA NON-SELECTIVE BLOCKER, 2018-2030 (USD MILLION)
  • TABLE 46. BRAZIL BETA BLOCKERS MARKET SIZE, BY BETA-1 SELECTIVE BLOCKER, 2018-2030 (USD MILLION)
  • TABLE 47. BRAZIL BETA BLOCKERS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 48. BRAZIL BETA BLOCKERS MARKET SIZE, BY CARDIAC DISEASES, 2018-2030 (USD MILLION)
  • TABLE 49. BRAZIL BETA BLOCKERS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 50. CANADA BETA BLOCKERS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 51. CANADA BETA BLOCKERS MARKET SIZE, BY BETA NON-SELECTIVE BLOCKER, 2018-2030 (USD MILLION)
  • TABLE 52. CANADA BETA BLOCKERS MARKET SIZE, BY BETA-1 SELECTIVE BLOCKER, 2018-2030 (USD MILLION)
  • TABLE 53. CANADA BETA BLOCKERS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 54. CANADA BETA BLOCKERS MARKET SIZE, BY CARDIAC DISEASES, 2018-2030 (USD MILLION)
  • TABLE 55. CANADA BETA BLOCKERS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 56. MEXICO BETA BLOCKERS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 57. MEXICO BETA BLOCKERS MARKET SIZE, BY BETA NON-SELECTIVE BLOCKER, 2018-2030 (USD MILLION)
  • TABLE 58. MEXICO BETA BLOCKERS MARKET SIZE, BY BETA-1 SELECTIVE BLOCKER, 2018-2030 (USD MILLION)
  • TABLE 59. MEXICO BETA BLOCKERS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 60. MEXICO BETA BLOCKERS MARKET SIZE, BY CARDIAC DISEASES, 2018-2030 (USD MILLION)
  • TABLE 61. MEXICO BETA BLOCKERS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 62. UNITED STATES BETA BLOCKERS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 63. UNITED STATES BETA BLOCKERS MARKET SIZE, BY BETA NON-SELECTIVE BLOCKER, 2018-2030 (USD MILLION)
  • TABLE 64. UNITED STATES BETA BLOCKERS MARKET SIZE, BY BETA-1 SELECTIVE BLOCKER, 2018-2030 (USD MILLION)
  • TABLE 65. UNITED STATES BETA BLOCKERS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 66. UNITED STATES BETA BLOCKERS MARKET SIZE, BY CARDIAC DISEASES, 2018-2030 (USD MILLION)
  • TABLE 67. UNITED STATES BETA BLOCKERS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 68. UNITED STATES BETA BLOCKERS MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
  • TABLE 69. ASIA-PACIFIC BETA BLOCKERS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 70. ASIA-PACIFIC BETA BLOCKERS MARKET SIZE, BY BETA NON-SELECTIVE BLOCKER, 2018-2030 (USD MILLION)
  • TABLE 71. ASIA-PACIFIC BETA BLOCKERS MARKET SIZE, BY BETA-1 SELECTIVE BLOCKER, 2018-2030 (USD MILLION)
  • TABLE 72. ASIA-PACIFIC BETA BLOCKERS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 73. ASIA-PACIFIC BETA BLOCKERS MARKET SIZE, BY CARDIAC DISEASES, 2018-2030 (USD MILLION)
  • TABLE 74. ASIA-PACIFIC BETA BLOCKERS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 75. ASIA-PACIFIC BETA BLOCKERS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 76. AUSTRALIA BETA BLOCKERS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 77. AUSTRALIA BETA BLOCKERS MARKET SIZE, BY BETA NON-SELECTIVE BLOCKER, 2018-2030 (USD MILLION)
  • TABLE 78. AUSTRALIA BETA BLOCKERS MARKET SIZE, BY BETA-1 SELECTIVE BLOCKER, 2018-2030 (USD MILLION)
  • TABLE 79. AUSTRALIA BETA BLOCKERS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 80. AUSTRALIA BETA BLOCKERS MARKET SIZE, BY CARDIAC DISEASES, 2018-2030 (USD MILLION)
  • TABLE 81. AUSTRALIA BETA BLOCKERS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 82. CHINA BETA BLOCKERS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 83. CHINA BETA BLOCKERS MARKET SIZE, BY BETA NON-SELECTIVE BLOCKER, 2018-2030 (USD MILLION)
  • TABLE 84. CHINA BETA BLOCKERS MARKET SIZE, BY BETA-1 SELECTIVE BLOCKER, 2018-2030 (USD MILLION)
  • TABLE 85. CHINA BETA BLOCKERS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 86. CHINA BETA BLOCKERS MARKET SIZE, BY CARDIAC DISEASES, 2018-2030 (USD MILLION)
  • TABLE 87. CHINA BETA BLOCKERS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 88. INDIA BETA BLOCKERS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 89. INDIA BETA BLOCKERS MARKET SIZE, BY BETA NON-SELECTIVE BLOCKER, 2018-2030 (USD MILLION)
  • TABLE 90. INDIA BETA BLOCKERS MARKET SIZE, BY BETA-1 SELECTIVE BLOCKER, 2018-2030 (USD MILLION)
  • TABLE 91. INDIA BETA BLOCKERS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 92. INDIA BETA BLOCKERS MARKET SIZE, BY CARDIAC DISEASES, 2018-2030 (USD MILLION)
  • TABLE 93. INDIA BETA BLOCKERS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 94. INDONESIA BETA BLOCKERS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 95. INDONESIA BETA BLOCKERS MARKET SIZE, BY BETA NON-SELECTIVE BLOCKER, 2018-2030 (USD MILLION)
  • TABLE 96. INDONESIA BETA BLOCKERS MARKET SIZE, BY BETA-1 SELECTIVE BLOCKER, 2018-2030 (USD MILLION)
  • TABLE 97. INDONESIA BETA BLOCKERS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 98. INDONESIA BETA BLOCKERS MARKET SIZE, BY CARDIAC DISEASES, 2018-2030 (USD MILLION)
  • TABLE 99. INDONESIA BETA BLOCKERS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 100. JAPAN BETA BLOCKERS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 101. JAPAN BETA BLOCKERS MARKET SIZE, BY BETA NON-SELECTIVE BLOCKER, 2018-2030 (USD MILLION)
  • TABLE 102. JAPAN BETA BLOCKERS MARKET SIZE, BY BETA-1 SELECTIVE BLOCKER, 2018-2030 (USD MILLION)
  • TABLE 103. JAPAN BETA BLOCKERS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 104. JAPAN BETA BLOCKERS MARKET SIZE, BY CARDIAC DISEASES, 2018-2030 (USD MILLION)
  • TABLE 105. JAPAN BETA BLOCKERS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 106. MALAYSIA BETA BLOCKERS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 107. MALAYSIA BETA BLOCKERS MARKET SIZE, BY BETA NON-SELECTIVE BLOCKER, 2018-2030 (USD MILLION)
  • TABLE 108. MALAYSIA BETA BLOCKERS MARKET SIZE, BY BETA-1 SELECTIVE BLOCKER, 2018-2030 (USD MILLION)
  • TABLE 109. MALAYSIA BETA BLOCKERS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 110. MALAYSIA BETA BLOCKERS MARKET SIZE, BY CARDIAC DISEASES, 2018-2030 (USD MILLION)
  • TABLE 111. MALAYSIA BETA BLOCKERS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 112. PHILIPPINES BETA BLOCKERS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 113. PHILIPPINES BETA BLOCKERS MARKET SIZE, BY BETA NON-SELECTIVE BLOCKER, 2018-2030 (USD MILLION)
  • TABLE 114. PHILIPPINES BETA BLOCKERS MARKET SIZE, BY BETA-1 SELECTIVE BLOCKER, 2018-2030 (USD MILLION)
  • TABLE 115. PHILIPPINES BETA BLOCKERS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 116. PHILIPPINES BETA BLOCKERS MARKET SIZE, BY CARDIAC DISEASES, 2018-2030 (USD MILLION)
  • TABLE 117. PHILIPPINES BETA BLOCKERS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 118. SINGAPORE BETA BLOCKERS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 119. SINGAPORE BETA BLOCKERS MARKET SIZE, BY BETA NON-SELECTIVE BLOCKER, 2018-2030 (USD MILLION)
  • TABLE 120. SINGAPORE BETA BLOCKERS MARKET SIZE, BY BETA-1 SELECTIVE BLOCKER, 2018-2030 (USD MILLION)
  • TABLE 121. SINGAPORE BETA BLOCKERS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 122. SINGAPORE BETA BLOCKERS MARKET SIZE, BY CARDIAC DISEASES, 2018-2030 (USD MILLION)
  • TABLE 123. SINGAPORE BETA BLOCKERS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 124. SOUTH KOREA BETA BLOCKERS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 125. SOUTH KOREA BETA BLOCKERS MARKET SIZE, BY BETA NON-SELECTIVE BLOCKER, 2018-2030 (USD MILLION)
  • TABLE 126. SOUTH KOREA BETA BLOCKERS MARKET SIZE, BY BETA-1 SELECTIVE BLOCKER, 2018-2030 (USD MILLION)
  • TABLE 127. SOUTH KOREA BETA BLOCKERS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 128. SOUTH KOREA BETA BLOCKERS MARKET SIZE, BY CARDIAC DISEASES, 2018-2030 (USD MILLION)
  • TABLE 129. SOUTH KOREA BETA BLOCKERS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 130. TAIWAN BETA BLOCKERS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 131. TAIWAN BETA BLOCKERS MARKET SIZE, BY BETA NON-SELECTIVE BLOCKER, 2018-2030 (USD MILLION)
  • TABLE 132. TAIWAN BETA BLOCKERS MARKET SIZE, BY BETA-1 SELECTIVE BLOCKER, 2018-2030 (USD MILLION)
  • TABLE 133. TAIWAN BETA BLOCKERS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 134. TAIWAN BETA BLOCKERS MARKET SIZE, BY CARDIAC DISEASES, 2018-2030 (USD MILLION)
  • TABLE 135. TAIWAN BETA BLOCKERS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 136. THAILAND BETA BLOCKERS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 137. THAILAND BETA BLOCKERS MARKET SIZE, BY BETA NON-SELECTIVE BLOCKER, 2018-2030 (USD MILLION)
  • TABLE 138. THAILAND BETA BLOCKERS MARKET SIZE, BY BETA-1 SELECTIVE BLOCKER, 2018-2030 (USD MILLION)
  • TABLE 139. THAILAND BETA BLOCKERS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 140. THAILAND BETA BLOCKERS MARKET SIZE, BY CARDIAC DISEASES, 2018-2030 (USD MILLION)
  • TABLE 141. THAILAND BETA BLOCKERS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 142. VIETNAM BETA BLOCKERS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 143. VIETNAM BETA BLOCKERS MARKET SIZE, BY BETA NON-SELECTIVE BLOCKER, 2018-2030 (USD MILLION)
  • TABLE 144. VIETNAM BETA BLOCKERS MARKET SIZE, BY BETA-1 SELECTIVE BLOCKER, 2018-2030 (USD MILLION)
  • TABLE 145. VIETNAM BETA BLOCKERS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 146. VIETNAM BETA BLOCKERS MARKET SIZE, BY CARDIAC DISEASES, 2018-2030 (USD MILLION)
  • TABLE 147. VIETNAM BETA BLOCKERS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 148. EUROPE, MIDDLE EAST & AFRICA BETA BLOCKERS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 149. EUROPE, MIDDLE EAST & AFRICA BETA BLOCKERS MARKET SIZE, BY BETA NON-SELECTIVE BLOCKER, 2018-2030 (USD MILLION)
  • TABLE 150. EUROPE, MIDDLE EAST & AFRICA BETA BLOCKERS MARKET SIZE, BY BETA-1 SELECTIVE BLOCKER, 2018-2030 (USD MILLION)
  • TABLE 151. EUROPE, MIDDLE EAST & AFRICA BETA BLOCKERS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 152. EUROPE, MIDDLE EAST & AFRICA BETA BLOCKERS MARKET SIZE, BY CARDIAC DISEASES, 2018-2030 (USD MILLION)
  • TABLE 153. EUROPE, MIDDLE EAST & AFRICA BETA BLOCKERS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 154. EUROPE, MIDDLE EAST & AFRICA BETA BLOCKERS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 155. DENMARK BETA BLOCKERS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 156. DENMARK BETA BLOCKERS MARKET SIZE, BY BETA NON-SELECTIVE BLOCKER, 2018-2030 (USD MILLION)
  • TABLE 157. DENMARK BETA BLOCKERS MARKET SIZE, BY BETA-1 SELECTIVE BLOCKER, 2018-2030 (USD MILLION)
  • TABLE 158. DENMARK BETA BLOCKERS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 159. DENMARK BETA BLOCKERS MARKET SIZE, BY CARDIAC DISEASES, 2018-2030 (USD MILLION)
  • TABLE 160. DENMARK BETA BLOCKERS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 161. EGYPT BETA BLOCKERS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 162. EGYPT BETA BLOCKERS MARKET SIZE, BY BETA NON-SELECTIVE BLOCKER, 2018-2030 (USD MILLION)
  • TABLE 163. EGYPT BETA BLOCKERS MARKET SIZE, BY BETA-1 SELECTIVE BLOCKER, 2018-2030 (USD MILLION)
  • TABLE 164. EGYPT BETA BLOCKERS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 165. EGYPT BETA BLOCKERS MARKET SIZE, BY CARDIAC DISEASES, 2018-2030 (USD MILLION)
  • TABLE 166. EGYPT BETA BLOCKERS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 167. FINLAND BETA BLOCKERS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 168. FINLAND BETA BLOCKERS MARKET SIZE, BY BETA NON-SELECTIVE BLOCKER, 2018-2030 (USD MILLION)
  • TABLE 169. FINLAND BETA BLOCKERS MARKET SIZE, BY BETA-1 SELECTIVE BLOCKER, 2018-2030 (USD MILLION)
  • TABLE 170. FINLAND BETA BLOCKERS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 171. FINLAND BETA BLOCKERS MARKET SIZE, BY CARDIAC DISEASES, 2018-2030 (USD MILLION)
  • TABLE 172. FINLAND BETA BLOCKERS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 173. FRANCE BETA BLOCKERS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 174. FRANCE BETA BLOCKERS MARKET SIZE, BY BETA NON-SELECTIVE BLOCKER, 2018-2030 (USD MILLION)
  • TABLE 175. FRANCE BETA BLOCKERS MARKET SIZE, BY BETA-1 SELECTIVE BLOCKER, 2018-2030 (USD MILLION)
  • TABLE 176. FRANCE BETA BLOCKERS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 177. FRANCE BETA BLOCKERS MARKET SIZE, BY CARDIAC DISEASES, 2018-2030 (USD MILLION)
  • TABLE 178. FRANCE BETA BLOCKERS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 179. GERMANY BETA BLOCKERS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 180. GERMANY BETA BLOCKERS MARKET SIZE, BY BETA NON-SELECTIVE BLOCKER, 2018-2030 (USD MILLION)
  • TABLE 181. GERMANY BETA BLOCKERS MARKET SIZE, BY BETA-1 SELECTIVE BLOCKER, 2018-2030 (USD MILLION)
  • TABLE 182. GERMANY BETA BLOCKERS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 183. GERMANY BETA BLOCKERS MARKET SIZE, BY CARDIAC DISEASES, 2018-2030 (USD MILLION)
  • TABLE 184. GERMANY BETA BLOCKERS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 185. ISRAEL BETA BLOCKERS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 186. ISRAEL BETA BLOCKERS MARKET SIZE, BY BETA NON-SELECTIVE BLOCKER, 2018-2030 (USD MILLION)
  • TABLE 187. ISRAEL BETA BLOCKERS MARKET SIZE, BY BETA-1 SELECTIVE BLOCKER, 2018-2030 (USD MILLION)
  • TABLE 188. ISRAEL BETA BLOCKERS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 189. ISRAEL BETA BLOCKERS MARKET SIZE, BY CARDIAC DISEASES, 2018-2030 (USD MILLION)
  • TABLE 190. ISRAEL BETA BLOCKERS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 191. ITALY BETA BLOCKERS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 192. ITALY BETA BLOCKERS MARKET SIZE, BY BETA NON-SELECTIVE BLOCKER, 2018-2030 (USD MILLION)
  • TABLE 193. ITALY BETA BLOCKERS MARKET SIZE, BY BETA-1 SELECTIVE BLOCKER, 2018-2030 (USD MILLION)
  • TABLE 194. ITALY BETA BLOCKERS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 195. ITALY BETA BLOCKERS MARKET SIZE, BY CARDIAC DISEASES, 2018-2030 (USD MILLION)
  • TABLE 196. ITALY BETA BLOCKERS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 197. NETHERLANDS BETA BLOCKERS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 198. NETHERLANDS BETA BLOCKERS MARKET SIZE, BY BETA NON-SELECTIVE BLOCKER, 2018-2030 (USD MILLION)
  • TABLE 199. NETHERLANDS BETA BLOCKERS MARKET SIZE, BY BETA-1 SELECTIVE BLOCKER, 2018-2030 (USD MILLION)
  • TABLE 200. NETHERLANDS BETA BLOCKERS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 201. NETHERLANDS BETA BLOCKERS MARKET SIZE, BY CARDIAC DISEASES, 2018-2030 (USD MILLION)
  • TABLE 202. NETHERLANDS BETA BLOCKERS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 203. NIGERIA BETA BLOCKERS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 204. NIGERIA BETA BLOCKERS MARKET SIZE, BY BETA NON-SELECTIVE BLOCKER, 2018-2030 (USD MILLION)
  • TABLE 205. NIGERIA BETA BLOCKERS MARKET SIZE, BY BETA-1 SELECTIVE BLOCKER, 2018-2030 (USD MILLION)
  • TABLE 206. NIGERIA BETA BLOCKERS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 207. NIGERIA BETA BLOCKERS MARKET SIZE, BY CARDIAC DISEASES, 2018-2030 (USD MILLION)
  • TABLE 208. NIGERIA BETA BLOCKERS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 209. NORWAY BETA BLOCKERS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 210. NORWAY BETA BLOCKERS MARKET SIZE, BY BETA NON-SELECTIVE BLOCKER, 2018-2030 (USD MILLION)
  • TABLE 211. NORWAY BETA BLOCKERS MARKET SIZE, BY BETA-1 SELECTIVE BLOCKER, 2018-2030 (USD MILLION)
  • TABLE 212. NORWAY BETA BLOCKERS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 213. NORWAY BETA BLOCKERS MARKET SIZE, BY CARDIAC DISEASES, 2018-2030 (USD MILLION)
  • TABLE 214. NORWAY BETA BLOCKERS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 215. POLAND BETA BLOCKERS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 216. POLAND BETA BLOCKERS MARKET SIZE, BY BETA NON-SELECTIVE BLOCKER, 2018-2030 (USD MILLION)
  • TABLE 217. POLAND BETA BLOCKERS MARKET SIZE, BY BETA-1 SELECTIVE BLOCKER, 2018-2030 (USD MILLION)
  • TABLE 218. POLAND BETA BLOCKERS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 219. POLAND BETA BLOCKERS MARKET SIZE, BY CARDIAC DISEASES, 2018-2030 (USD MILLION)
  • TABLE 220. POLAND BETA BLOCKERS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 221. QATAR BETA BLOCKERS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 222. QATAR BETA BLOCKERS MARKET SIZE, BY BETA NON-SELECTIVE BLOCKER, 2018-2030 (USD MILLION)
  • TABLE 223. QATAR BETA BLOCKERS MARKET SIZE, BY BETA-1 SELECTIVE BLOCKER, 2018-2030 (USD MILLION)
  • TABLE 224. QATAR BETA BLOCKERS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 225. QATAR BETA BLOCKERS MARKET SIZE, BY CARDIAC DISEASES, 2018-2030 (USD MILLION)
  • TABLE 226. QATAR BETA BLOCKERS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 227. RUSSIA BETA BLOCKERS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 228. RUSSIA BETA BLOCKERS MARKET SIZE, BY BETA NON-SELECTIVE BLOCKER, 2018-2030 (USD MILLION)
  • TABLE 229. RUSSIA BETA BLOCKERS MARKET SIZE, BY BETA-1 SELECTIVE BLOCKER, 2018-2030 (USD MILLION)
  • TABLE 230. RUSSIA BETA BLOCKERS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 231. RUSSIA BETA BLOCKERS MARKET SIZE, BY CARDIAC DISEASES, 2018-2030 (USD MILLION)
  • TABLE 232. RUSSIA BETA BLOCKERS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 233. SAUDI ARABIA BETA BLOCKERS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 234. SAUDI ARABIA BETA BLOCKERS MARKET SIZE, BY BETA NON-SELECTIVE BLOCKER, 2018-2030 (USD MILLION)
  • TABLE 235. SAUDI ARABIA BETA BLOCKERS MARKET SIZE, BY BETA-1 SELECTIVE BLOCKER, 2018-2030 (USD MILLION)
  • TABLE 236. SAUDI ARABIA BETA BLOCKERS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 237. SAUDI ARABIA BETA BLOCKERS MARKET SIZE, BY CARDIAC DISEASES, 2018-2030 (USD MILLION)
  • TABLE 238. SAUDI ARABIA BETA BLOCKERS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 239. SOUTH AFRICA BETA BLOCKERS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 240. SOUTH AFRICA BETA BLOCKERS MARKET SIZE, BY BETA NON-SELECTIVE BLOCKER, 2018-2030 (USD MILLION)
  • TABLE 241. SOUTH AFRICA BETA BLOCKERS MARKET SIZE, BY BETA-1 SELECTIVE BLOCKER, 2018-2030 (USD MILLION)
  • TABLE 242. SOUTH AFRICA BETA BLOCKERS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 243. SOUTH AFRICA BETA BLOCKERS MARKET SIZE, BY CARDIAC DISEASES, 2018-2030 (USD MILLION)
  • TABLE 244. SOUTH AFRICA BETA BLOCKERS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 245. SPAIN BETA BLOCKERS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 246. SPAIN BETA BLOCKERS MARKET SIZE, BY BETA NON-SELECTIVE BLOCKER, 2018-2030 (USD MILLION)
  • TABLE 247. SPAIN BETA BLOCKERS MARKET SIZE, BY BETA-1 SELECTIVE BLOCKER, 2018-2030 (USD MILLION)
  • TABLE 248. SPAIN BETA BLOCKERS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 249. SPAIN BETA BLOCKERS MARKET SIZE, BY CARDIAC DISEASES, 2018-2030 (USD MILLION)
  • TABLE 250. SPAIN BETA BLOCKERS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 251. SWEDEN BETA BLOCKERS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 252. SWEDEN BETA BLOCKERS MARKET SIZE, BY BETA NON-SELECTIVE BLOCKER, 2018-2030 (USD MILLION)
  • TABLE 253. SWEDEN BETA BLOCKERS MARKET SIZE, BY BETA-1 SELECTIVE BLOCKER, 2018-2030 (USD MILLION)
  • TABLE 254. SWEDEN BETA BLOCKERS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 255. SWEDEN BETA BLOCKERS MARKET SIZE, BY CARDIAC DISEASES, 2018-2030 (USD MILLION)
  • TABLE 256. SWEDEN BETA BLOCKERS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 257. SWITZERLAND BETA BLOCKERS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 258. SWITZERLAND BETA BLOCKERS MARKET SIZE, BY BETA NON-SELECTIVE BLOCKER, 2018-2030 (USD MILLION)
  • TABLE 259. SWITZERLAND BETA BLOCKERS MARKET SIZE, BY BETA-1 SELECTIVE BLOCKER, 2018-2030 (USD MILLION)
  • TABLE 260. SWITZERLAND BETA BLOCKERS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 261. SWITZERLAND BETA BLOCKERS MARKET SIZE, BY CARDIAC DISEASES, 2018-2030 (USD MILLION)
  • TABLE 262. SWITZERLAND BETA BLOCKERS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 263. TURKEY BETA BLOCKERS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 264. TURKEY BETA BLOCKERS MARKET SIZE, BY BETA NON-SELECTIVE BLOCKER, 2018-2030 (USD MILLION)
  • TABLE 265. TURKEY BETA BLOCKERS MARKET SIZE, BY BETA-1 SELECTIVE BLOCKER, 2018-2030 (USD MILLION)
  • TABLE 266. TURKEY BETA BLOCKERS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 267. TURKEY BETA BLOCKERS MARKET SIZE, BY CARDIAC DISEASES, 2018-2030 (USD MILLION)
  • TABLE 268. TURKEY BETA BLOCKERS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 269. UNITED ARAB EMIRATES BETA BLOCKERS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 270. UNITED ARAB EMIRATES BETA BLOCKERS MARKET SIZE, BY BETA NON-SELECTIVE BLOCKER, 2018-2030 (USD MILLION)
  • TABLE 271. UNITED ARAB EMIRATES BETA BLOCKERS MARKET SIZE, BY BETA-1 SELECTIVE BLOCKER, 2018-2030 (USD MILLION)
  • TABLE 272. UNITED ARAB EMIRATES BETA BLOCKERS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 273. UNITED ARAB EMIRATES BETA BLOCKERS MARKET SIZE, BY CARDIAC DISEASES, 2018-2030 (USD MILLION)
  • TABLE 274. UNITED ARAB EMIRATES BETA BLOCKERS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 275. UNITED KINGDOM BETA BLOCKERS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 276. UNITED KINGDOM BETA BLOCKERS MARKET SIZE, BY BETA NON-SELECTIVE BLOCKER, 2018-2030 (USD MILLION)
  • TABLE 277. UNITED KINGDOM BETA BLOCKERS MARKET SIZE, BY BETA-1 SELECTIVE BLOCKER, 2018-2030 (USD MILLION)
  • TABLE 278. UNITED KINGDOM BETA BLOCKERS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 279. UNITED KINGDOM BETA BLOCKERS MARKET SIZE, BY CARDIAC DISEASES, 2018-2030 (USD MILLION)
  • TABLE 280. UNITED KINGDOM BETA BLOCKERS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 281. BETA BLOCKERS MARKET SHARE, BY KEY PLAYER, 2023
  • TABLE 282. BETA BLOCKERS MARKET, FPNV POSITIONING MATRIX, 2023